Skip to content

← All news

Closing the Funding and Diagnostic Gap: Why Uniting Capital, Community, and Clinical Action is Essential to Stop AMR

17 November 2026

Jump to

Closing the Funding and Diagnostic Gap: Why Uniting Capital, Community, and Clinical Action is Essential to Stop AMR

Antimicrobial Resistance (AMR) is no longer a distant threat—it is a present-day global health and economic crisis. According to the latest assessment released by the World Health Organization (WHO) from the Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS), drug-resistant bacterial infections could cause up to 39 million deaths by 2050 without urgent, coordinated intervention.

In 2021 alone, bacterial AMR was directly responsible for over 1 million deaths and associated with nearly 4.7 million deaths. As Dr. Jean Pierre Nyemazi, acting director of WHO’s AMR department, highlighted, the clinical pipeline for new treatments is failing to keep pace with rising resistance, rendering routine infections longer to treat, more toxic, and significantly more expensive.

At the World Health Innovation Summit (WHIS), we view AMR not only as a clinical challenge, but as a systemic $100 trillion macroeconomic threat to global security, on par with climate change.


The Reality Gap: 183 National Plans, Only 22% Funded Over the past decade, nations have made commendable structural progress. Out of 194 countries, 183 responded to the 2026 WHO survey and confirmed having a national AMR action plan in place. However, the data reveals a critical implementation bottleneck: only 42 countries (22%) have actually allocated funding to finance their plans. As WHO Technical Officer Pravarsha Prakash noted, while the TrACSS survey brings multi-sectoral leaders around the table to map gaps at the national level and measure progress toward UN General Assembly targets, a plan without allocated capital cannot save lives at the bedside or in the community.


Laboratory Testing and Diagnostic Blind Spots Beyond the funding shortfall, surveillance capacity remains dangerously uneven across the globe:

  • Bacterial Testing Limits: While 131 countries (72%) have the capacity to test for selected monitored bacteria, more than one in four countries cannot test for resistance in monitored bacteria even in their best-equipped capital-city laboratories.
  • Fungal Testing Gaps: Fungal infections face a severe lack of attention and resources. Only 72 countries (39%) currently possess the capacity to test for selected fungal pathogens—less than half of the global 2030 target, which aims for 80% of countries to test across all monitored bacterial and fungal pathogens.

To address these surveillance blind spots, the WHO has rolled out the AMR Diagnostic Initiative, offering countries a prioritized blueprint of essential diagnostic tests to detect resistance early.


The One Health Mandate: Investing in Social Determinants of Health While 113 countries now monitor antibiotic usage nationally and 109 have standardized AMR surveillance systems, hospital guidelines alone are insufficient without actionable feedback loops and holistic prevention.

Tackling AMR requires addressing the underlying social determinants of health through a robust One Health model:

  1. **Infection Prevention & Control (IPC) and Hygiene:**Ensuring access to clean water, sanitation, and hygiene (WASH) facilities prevents infections before they occur, directly reducing reliance on antimicrobials.
  2. **Clinical Decision Support & Behavioral Protocols:**Implementing standardized clinical pathways—such as the Sepsis Six protocol championed by WHIS Clinical Lead Dr. Ron Daniels BEM—reduces unnecessary prescribing while catching severe infections early.
  3. Agri-Food & Environmental Stewardship: Overuse of antibiotics in livestock and agricultural runoff directly drives environmental resistance, requiring strict supply chain oversight.
  4. Community Social Prescribing: Promoting community-level health literacy, hygiene awareness, and non-clinical care pathways lowers primary care demand and protects drug efficacy.

Capital to Community: The WHIS Response & The Road to Venice 2027 Ahead of World AMR Awareness Week 2026 (18–24 November), WHIS is advocating for innovative financing structures to bridge the gap between global capital and frontline delivery:

  • Blended Finance & The 1% AMR Stewardship Pledge: Enabling institutional capital, family offices, and corporate partners to dedicate resources toward scaling local diagnostic networks and community prevention.
  • World Health Innovation Summit Venice 2027: Partnering with MARE eHealth Technopark to convene global policy makers, sovereign wealth funds, and clinical leaders to reframe AMR as an investable global health security priority.

The warning from global health authorities is clear: without funded action, rapid diagnostic scaling, and cross-sector stewardship, millions of lives will be lost to treatable infections.


Join the Conversation: Explore how WHIS is advancing global health stewardship and blended finance solutions at whis.world/f/the-100-trillion-threat.

Older story → The World Health Service (WHS) is the not-for-profit arm of World Health Innovation Summit